KEGG image  Antineoplastics

[ Brite table menu ]
[ English | Japanese ]

Class Generic name ATC KEGG Products (USA) Products (Japan) Indications (USA)
Molecularly targeted agent Monoclonal antibody Rituximab L01XC02 D02994 RITUXAN RITUXAN CD20-positive non–Hodgkin's lymphoma
Chronic lymphocytic leukemia
Rheumatoid arthritis
Granulomatosis with polyangiitis (Wegener's granulomatosis) and microscopic polyangiitis
Trastuzumab L01XC03 D03257 HERCEPTIN HERCEPTIN HER2-overexpressing adjuvant breast cancer
HER2-overexpressing metastatic breast cancer
HER2-overexpressing metastatic gastric cancer
L01XC14 D09980 KADCYLA KADCYLA HER2-positive metastatic breast cancer
Gemtuzumab L01XC05 D03259 MYLOTARG
Cetuximab L01XC06 D03455 ERBITUX ERBITUX Squamous cell carcinoma of the head and neck
K-Ras mutation-negative, EGFR-expressing colorectal cancer
Bevacizumab L01XC07 D06409 AVASTIN AVASTIN Metastatic colorectal cancer
Non-squamous non–small cell lung cancer
Metastatic renal cell carcinoma
Persistent, recurrent, or metastatic carcinoma of the cervix
Platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Panitumumab L01XC08 D05350 VECTIBIX VECTIBIX K-Ras mutation negative metastatic colorectal cancer
Ofatumumab L01XC10 D09314 ARZERRA ARZERRA Previously untreated chronic lymphocytic leukemia
Refractory chronic lymphocytic leukemia
Ipilimumab L01XC11 D04603 YERVOY YERVOY Unresectable or metastatic melanoma
Brentuximab L01XC12 D09587 ADCETRIS ADCETRIS Hodgkin lymphoma
Systemic anaplastic large cell lymphoma
Pertuzumab L01XC13 D05446 PERJETA PERJETA HER2-positive metastatic breast cancer
Neoadjuvant treatment of HER2-positive, locally advanced, inflammatory, or early stage breast cancer
Obinutuzumab L01XC15 D09321 GAZYVA Previously untreated chronic lymphocytic leukemia
Dinutuximab L01XC16 D10559 UNITUXIN Pediatric high-risk neuroblastoma
Nivolumab L01XC17 D10316 OPDIVO OPDIVO Unresectable or metastatic melanoma
Pembrolizumab L01XC18 D10574 KEYTRUDA KEYTRUDA Unresectable or metastatic melanoma
Blinatumomab L01XC19 D09325 BLINCYTO Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Ramucirumab L01XC21 D09371 CYRAMZA CYRAMZA Gastric cancer
Non-small cell lung cancer
Necitumumab L01XC22 D10018 PORTRAZZA Squamous non-small cell lung cancer (NSCLC)
Alemtuzumab L04AA34 D02802 CAMPATH MABCAMPATH B-cell chronic lymphocytic leukemia
Ibritumomab V10XX02 D04489 ZEVALIN ZEVALIN Relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma
Previously untreated follicular non-Hodgkin's lymphoma
Elotuzumab D09337 EMPLICITI EMPLICITI Multiple myeloma
Mogamulizumab D09761 POTELIGEO
Atezolizumab D10773 TECENTRIQ Locally advanced or metastatic urothelial carcinoma
Olaratumab D09939 LARTRUVO Soft tissue sarcoma
Tyrosine kinase inhibitor Imatinib L01XE01 D01441 GLEEVEC GLIVEC Philadelphia chromosome positive chronic myeloid leukemia
Philadelphia chromosome positive acute lymphoblastic leukemia
Myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangements
Aggressive systemic mastocytosis without c-Kit mutation D816V
Hypereosinophilic syndrome and/or chronic eosinophilic leukemia with FIP1L1-PDGFRα fusion kinase
Unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans
Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors
Gefitinib L01XE02 D01977 IRESSA IRESSA Locally advanced or metastatic non-small cell lung cancer
Erlotinib L01XE03 D04023 TARCEVA TARCEVA Metastatic non-small cell lung cancer
Locally advanced, unresectable or metastatic pancreatic cancer
Sunitinib L01XE04 D06402 SUTENT SUTENT Gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate
Advanced renal cell carcinoma
Progressive, well-differentiated pancreatic neuroendocrine tumors
Sorafenib L01XE05 D06272 NEXAVAR NEXAVAR Unresectable hepatocellular carcinoma
Advanced renal cell carcinoma
Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma
Dasatinib L01XE06 D06414 SPRYCEL SPRYCEL Philadelphia chromosome-positive chronic myeloid leukemia
Chronic, accelerated, or myeloid or lymphoid blast phase Philadelphia chromosome-positive chronic myeloid leukemia
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
Lapatinib L01XE07 D04024 TYKERB TYKERB HER2-overexpressing advanced or metastatic breast cancer
Nilotinib L01XE08 D06413 TASIGNA TASIGNA Philadelphia chromosome positive chronic myeloid leukemia
Pazopanib L01XE11 D05380 VOTRIENT VOTRIENT Advanced renal cell carcinoma
Advanced soft tissue sarcoma
Vandetanib L01XE12 D06407 CAPRELSA CAPRELSA Symptomatic or progressive medullary thyroid cancer
Afatinib L01XE13 D09733 GILOTRIF GILOTRIF Metastatic non-small cell lung cancer with EGFR exon 19 deletion or exon 21 (L858R) substitution mutation
Bosutinib L01XE14 D09728 BOSULIF BOSULIF Chronic, accelerated, or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia
Crizotinib L01XE16 D09731 XALKORI XALKORI ALK-positive metastatic non-small cell lung cancer
Axitinib L01XE17 D03218 INLYTA INLYTA Advanced renal cell carcinoma
Ruxolitinib L01XE18 D09960 JAKAFI JAKAVI Intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis
Polycythemia vera
Regorafenib L01XE21 D10137 STIVARGA STIVARGA Metastatic colorectal cancer
Locally advanced, unresectable or metastatic gastrointestinal stromal tumor
Ponatinib L01XE24 D09951 ICLUSIG ICLUSIG T315I-positive chronic myeloid leukemia
T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia
Cabozantinib L01XE26 D10095 COMETRIQ Progressive, metastatic medullary thyroid cancer
Ibrutinib L01XE27 D10223 IMBRUVICA IMBRUVICA Mantle cell lymphoma
Chronic lymphocytic leukemia
Chronic lymphocytic leukemia with 17p deletion
Waldenström's macroglobulinemia
Ceritinib L01XE28 D10551 ZYKADIA ZYKADIA ALK-positive metastatic non-small cell lung cancer
Lenvatinib L01XE29 D09920 LENVIMA LENVIMA Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer
Alectinib D10450 ALECENSA ALECENSA ALK-positive metastatic non-small cell lung cancer (NSCLC)
Osimertinib D10766 TAGRISSO TAGRISSO metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
mTOR kinase inhibitor Temsirolimus L01XE09 D06068 TORISEL TORISEL Advanced renal cell carcinoma
Everolimus L01XE10 L04AA18 D02714 AFINITOR AFINITOR Postmenopausal advanced hormone receptor-positive, HER2-negative breast cancer
Progressive neuroendocrine tumors of pancreatic origin
Advanced renal cell carcinoma
Renal angiomyolipoma and tuberous sclerosis complex
Subependymal giant cell astrocytoma
Other kinase inhibitor Vemurafenib L01XE15 D09996 ZELBORAF ZELBORAF Unresectable or metastatic melanoma with BRAF V600E mutation
Dabrafenib L01XE23 D10104 TAFINLAR TAFINLAR Unresectable or metastatic melanoma with BRAF V600E or V600K mutation
Trametinib L01XE25 D10176 MEKINIST MEKINIST Unresectable or metastatic melanoma with BRAF V600E or V600K mutation
Idelalisib L01XX47 D10560 ZYDELIG Relapsed chronic lymphocytic leukemia
Relapsed follicular B-cell non-Hodgkin lymphoma
Relapsed small lymphocytic lymphoma
Palbociclib D10372 IBRANCE Postmenopausal, ER-positive, HER2-negative advanced breast cancer
Cobimetinib D10615 COTELLIC Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
Proteasome inhibitor Bortezomib L01XX32 D03150 VELCADE VELCADE Multiple myeloma
Mantle cell lymphoma
Carfilzomib L01XX45 D08880 KYPROLIS KYPROLIS Multiple myeloma
Ixazomib L01XX50 D10131 NINLARO Multiple myeloma
Retinoic acid receptor agonist Tretinoin L01XX14 D00094 TRETINOIN VESANOID Acute promyelocytic leukemia with t(15;17) translocation and/or PML/RARα
Alitretinoin L01XX22 D02815 PANRETIN AIDS-related Kaposi's sarcoma
Bexarotene L01XX25 D03106 TARGRETIN TARGRETIN Cutaneous T-cell lymphoma
Tamibarotene D01418 AMNOLAKE
Smoothened (SMO) antagonist Vismodegib L01XX43 D09992 ERIVEDGE Metastatic or locally advanced basal cell carcinoma
VEGF inhibitor Aflibercept L01XX44 D09574 ZALTRAP Metastatic colorectal cancer
PARP inhibitor Olaparib D09730 LYNPARZA Advanced ovarian cancer with gBRCA mutation
Hormone and hormone antagonist Androgen Fluoxymesterone G03BA01 D00327 ANDROXY Primary hypogonadism (congenital or acquired)
Hypogonadotropic hypogonadism (congenital or acquired)
Delayed puberty
Metastatic mammary cancer
Androgen antagonist Flutamide L02BB01 D00586 FLUTAMIDE ODYNE Locally confined stage B2-C and stage D2 metastatic carcinoma of the prostate
Nilutamide L02BB02 D00965 NILANDRON Metastatic prostate cancer (stage D2)
Bicalutamide L02BB03 D00961 CASODEX CASODEX Stage D2 metastatic carcinoma of the prostate
Enzalutamide L02BB04 D10218 XTANDI XTANDI Metastatic castration-resistant prostate cancer
Estrogen Ethinylestradiol G03CA01 L02AA03 D00554 PROSEXOL
Estrogen antagonist Tamoxifen L02BA01 D00966 SOLTAMOX NOLVADEX Breast cancer
Toremifene L02BA02 D00967 FARESTON FARESTON Postmenopausal estrogen-receptor positive metastatic breast cancer
Fulvestrant L02BA03 D01161 FASLODEX FASLODEX Postmenopausal hormone receptor positive metastatic breast cancer
Gonadotropin-releasing hormone agonist Leuprorelin L02AE02 D00989 LUPRON DEPOT
LEUPLIN Advanced prostatic cancer
Goserelin L02AE03 D00573 ZOLADEX ZOLADEX Locally confined stage T2b-T4 (stage B2-C) carcinoma of the prostate
Advanced carcinoma of the prostate
Triptorelin L02AE04 D06248 TRELSTAR Advanced prostate cancer
Aromatase inhibitor Anastrozole L02BG03 D00960 ARIMIDEX ARIMIDEX Postmenopausal, hormone receptor-positive early breast cancer
Letrozole L02BG04 D00964 FEMARA FEMARA Postmenopausal hormone receptor positive early breast cancer
Exemestane L02BG06 D00963 AROMASIN AROMASIN Postmenopausal estrogen-receptor positive early breast cancer
Corticosteroid Prednisone A07EA03 H02AB07 D00473 RAYOS (Indications for neoplastic conditions only)
Acute leukemia
Aggressive lymphomas
Polypeptide hormone release suppression Octreotide H01CB02 D06495 SANDOSTATIN Acromegaly
Metastatic carcinoid tumors
Vasoactive intestinal peptide tumors
Progestin Medroxyprogesterone G03AC06 G03DA02 L02AB02 D00951 DEPO-PROVERA HYSRON
Inoperable, recurrent, and metastatic endometrial or renal carcinoma
Other hormone antagonist Degarelix L02BX02 D09400 FIRMAGON Advanced prostate cancer
Abiraterone L02BX03 D09701 ZYTIGA ZYTIGA Metastatic castration-resistant prostate cancer
Biologic response modifier (BRM) Interferone Interferon alfa natural L03AB01 D03305 OIF
Interferon beta natural L03AB02 D03304 FERON
Interferon gamma L03AB03 D00747
ACTIMMUNE IMUNOMAX Severe, malignant osteopetrosis
Interferon alfa-2b L03AB05 D02745 INTRON A INTRON A Hairy cell leukemia
Follicular lymphoma
Condylomata acuminata
AIDS-related Kaposi's sarcoma
Chronic hepatitis C
Interleukin Aldesleukin L03AC01 D00748 PROLEUKIN Metastatic renal cell carcinoma
Metastatic melanoma
Oprelvekin L03AC02 D05266 NEUMEGA Nonmyeloid malignancies
Denileukin diftitox L01XX29 D03682 ONTAK CD25-expressing persistent or recurrent cutaneous T-cell lymphoma
Colony stimulating factor Filgrastim L03AA02 D03235 NEUPOGEN GRAN Nonmyeloid malignancies
Acute myeloid leukemia
Sargramostim L03AA09 D05803 LEUKINE Acute myelogenous leukemia
Lenograstim L03AA10 D03247 NEUTROGIN
Pegfilgrastim L03AA13 D06889 NEULASTA G-LASTA Non‑myeloid malignancies
Hematopoietic stem cell mobilizer Plerixafor L03AX16 D08971 MOZOBIL Non-Hodgkin’s lymphoma
Multiple myeloma
Nonspecific immunomodulation Thalidomide L04AX02 D00754 THALOMID THALED 1.1 Multiple Myeloma 1.2 Erythema Nodosum Leprosum
Lenalidomide L04AX04 D04687
REVLIMID REVLIMID Multiple myeloma
Myelodysplastic syndromes
Mantle cell lymphoma
Pomalidomide L04AX06 D08976 POMALYST POMALYST Multiple myeloma
Alkylating agent Nitrogen mustard analog Cyclophosphamide L01AA01 D00287 CYCLOPHOSPHAMIDE ENDOXAN Malignant lymphomas (stages III and IV), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma
Multiple myeloma
Leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration)
Mycosis fungoides (advanced disease)
Neuroblastoma (disseminated disease)
Adenocarcinoma of the ovary
Carcinoma of the breast
Chlorambucil L01AA02 D00266 LEUKERAN Chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin’s disease
Melphalan L01AA03 D00369
ALKERAN ALKERAN Multiple myeloma
Non-resectable epithelial carcinoma of the ovary
Chlormethine L01AA05 D07671
Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma
Ifosfamide L01AA06 D00343 IFOSFAMIDE IFOMIDE Germ cell testicular cancer
Bendamustine L01AA09 D07085 TREANDA TREAKISYM Chronic lymphocytic leukemia
Non-Hodgkin lymphoma
Estramustine L01XX11 D02398
EMCYT ESTRACYT Metastatic and/or progressive carcinoma of the prostate
Alkyl sulfonate Busulfan L01AB01 D00248 BUSULFEX
BUSULFEX Chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia
Nitrosourea Carmustine L01AD01 D00254 GLIADEL GLIADEL High-grade malignant glioma
Lomustine L01AD02 D00363 CEENU Brain tumors (both primary and metastatic)
Streptozocin L01AD04 D05932 ZANOSAR ZANOSAR Metastatic islet cell carcinoma of the pancreas
Nimustine L01AD06 D01059 NIDRAN
Ranimustine L01AD07 D01760 CYMERIN
Triazene Temozolomide L01AX03 D06067 TEMODAR TEMODAL Glioblastoma multiforme
Refractory anaplastic astrocytoma
Dacarbazine L01AX04 D00288 DACARBAZINE DACARBAZINE Metastatic malignant melanoma
Platinum compound Cisplatin L01XA01 D00275 PLANTINOL BRIPLATIN
Metastatic testicular tumors
Metastatic ovarian tumors
Advanced bladder cancer
Carboplatin L01XA02 D01363 CARBOPLATIN PARAPLATIN Advanced ovarian carcinoma
Oxaliplatin L01XA03 D01790 OXALIPLATIN ELPLAT Stage III colon cancer
Advanced colorectal cancer
Nedaplatin D01416 AQUPLA
Antimetabolite Folic acid analog Methotrexate L01BA01 L04AX03 D00142
METHOTREXATE Gestational choriocarcinoma, chorio-adenoma destruens, hydatidiform mole
Breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), lung cancer (particularly squamous cell and small cell types)
Pemetrexed L01BA04 D06503
ALIMTA ALIMTA Nonsquamous non-small cell lung cancer
Pralatrexate L01BA05 D05589 FOLOTYN Relapsed or refractory peripheral T-cell lymphoma
Purine analog Mercaptopurine L01BB02 D00161 PURINETHOL LEUKERIN Acute lymphatic (lymphocytic, lymphoblastic) leukemia
Thioguanine L01BB03 D06109 TABLOID Acute nonlymphocytic leukemias
Cladribine L01BB04 D01370 CLADRIBINE LEUSTATIN Active hairy cell leukemia
Fludarabine L01BB05 D01907 OFORTA FLUDARA B-cell chronic lymphocytic leukemia
Clofarabine L01BB06 D03546 CLOLAR EVOLTRA Relapsed or refractory acute lymphoblastic leukemia
Nelarabine L01BB07 D05134 ARRANON ARRANON G T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma
Pentostatin L01XX08 D00155 NIPENT COFORIN Hairy cell leukemia
Pyrimidine analog Cytarabine L01BC01 D00168
Lymphomatous meningitis
Fluorouracil L01BC02 D00584 FLUOROURACIL 5-FU Multiple actinic or solar keratoses
Tegafur L01BC03 D01244 FUTRAFUL
Gemcitabine L01BC05 D01155 GEMZAR GEMZAR Advanced ovarian cancer
Metastatic breast cancer
Inoperable, locally advanced (stage IIIA or IIIB), or metastatic (stage IV) non-small cell lung cancer
Locally advanced (nonresectable stage II or stage III) or metastatic (stage IV) adenocarcinoma of the pancreas
Capecitabine L01BC06 D01223 XELODA XELODA Dukes' C colon cancer
Metastatic colorectal carcinoma
Metastatic breast cancer
Azacitidine L01BC07 D03021 VIDAZA VIDAZA Myelodysplastic syndromes
Decitabine L01BC08 D03665 DACOGEN Myelodysplastic syndromes
Floxuridine D04197 FLOXURIDINE Gastrointestinal adenocarcinoma metastatic to the liver
Tegafur, mixt L01BC53 D02131 UFT
D06399 TS-1
Trifluridine, mixt L01BC59 D10526 LONSURF
Enocitabine D01633 SUNRABIN
Doxifluridine D01309 FURTULON
Natural product Antibiotic Actinomycin L01DA01 D00214 COSMEGEN COSMEGEN Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma, metastatic nonseminomatous testicular cancer
Gestational trophoblastic neoplasia
Locally recurrent or locoregional solid malignancies
Doxorubicin L01DB01 D01275 DOXIL ADRIACIN
Ovarian cancer
AIDS-related Kaposi's sarcoma
Multiple myeloma
Daunorubicin L01DB02 D01264 DAUNORUBICIN HYDROCHLORIDE DAUNOMYCIN Acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid)
Epirubicin L01DB03 D02214 ELLENCE FARMORUBICIN Axillary node tumor involvement
Aclarubicin L01DB04 D01911 ACLACINON
Idarubicin L01DB06 D01747 IDAMYCIN PFS IDAMYCIN Acute myeloid leukemia
Mitoxantrone L01DB07 D02166 MITOXANTRONE NOVANTRON Advanced hormone-refractory prostate cancer
Acute nonlymphocytic (myelogenous, promyelocytic, monocytic, and erythroid) leukemia
Pirarubicin L01DB08 D08386 THERARUBICIN
Valrubicin L01DB09 D02697 VALSTAR BCG-refractory carcinoma in situ of the urinary bladder
Amrubicin L01DB10 D07100 CALSED
Bleomycin L01DC01 D02177
BLEOMYCIN BLEO Squamous cell carcinoma
Testicular carcinoma
Malignant pleural effusion
Mitomycin L01DC03 D00208 MITOMYCIN MITOMYCIN Disseminated adenocarcinoma of the stomach or pancreas
Ixabepilone L01DC04 D04645 IXEMPRA Locally advanced breast cancer
Peplomycin D02063 PEPLEO
Microtubule polymer stabilizer Paclitaxel L01CD01 D00491 ABRAXANE TAXOL
Metastatic breast cancer
Locally advanced or metastatic non-small cell lung cancer
Metastatic adenocarcinoma of the pancreas
Docetaxel L01CD02 D07866
Locally advanced or metastatic breast cancer
Locally advanced or metastatic non-small cell lung cancer
Androgen independent (hormone refractory) metastatic prostate cancer
Advanced gastric adenocarcinoma
Locally advanced squamous cell carcinoma of the head and neck
Cabazitaxel L01CD04 D09755
JEVTANA JEVTANA Hormone-refractory metastatic prostate cancer
Mitotic inhibitor Vinblastine L01CA01 D01068 VINBLASTINE SULFATE EXAL Generalized Hodgkin’s disease (stages III and IV)
Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated)
Histiocytic lymphoma
Mycosis fungoides (advanced stages)
Advanced carcinoma of the testis
Kaposi’s sarcoma
Letterer-Siwe disease (histiocytosis X)
Vincristine L01CA02 D02197 MARQIBO ONCOVIN Philadelphia chromosome-negative acute lymphoblastic leukemia
Vindesine L01CA03 D01769 FILDESIN
Vinorelbine L01CA04 D01935 NAVELBINE NAVELBINE Locally advanced or metastatic non-small cell lung cancer
Eribulin L01XX41 D08914 HALAVEN HALAVEN Metastatic breast cancer
Topoisomerase I inhibitor Topotecan L01XX17 D02168 TOPOTECAN HYCAMTIN Chemotherapy-sensitive small cell lung cancer
Stage IVB, recurrent or persistent carcinoma of the cervix
Irinotecan L01XX19 D01061 CAMPTOSAR CAMPTO
Metastatic carcinoma of the colon or rectum
Topoisomerase II inhibitor Etoposide L01CB01 D00125 ETOPOSIDE PESID
Refractory testicular tumors
small cell lung cancer
D04107 ETOPOPHOS Refractory testicular tumors
Small cell lung cancer
Teniposide L01CB02 D02698 VUMON Refractory childhood acute lymphoblastic leukemia
Sobuzoxane D01404 PERAZOLIN
Anti-tumor immunostimulation Picibanil D08756 PICIBANIL
Other Trabectedin L01CX01 D06199 YONDELIS YONDELIS
Miscellaneous agent Methylhydrazine Procarbazine L01XB01 D00478 MATULANE PROCARBAZINE HYDROCHLORIDE Stage III and IV Hodgkin's disease
Sensitizer used in photodynamic/radiation therapy Porfimer sodium L01XD01 D03327 PHOTOFRIN PHOTOFRIN Completely or partially obstructing esophageal cancer
Microinvasive endobronchial non-small-cell lung cancer
High-grade dysplasia in Barrett's esophagus
Aminolevulinic acid L01XD04 D02908 ALAGLIO
Radiotherapy Sodium iodide I 131 V10XA01 D02259 HICON SODIUM IODIDE Carcinoma of the thyroid
Sodium phosphate P 32 V10XX01 D05870 P32 SODIUM PHOSPHATE Chronic myelocytic leukemia
Chronic lymphocytic leukemia
Radium-223 dichloride V10XX03 D10398 XOFIGO XOFIGO Castration-resistant prostate cancer
Bisphosphonate Pamidronic acid M05BA03 D00941 PAMIDRONATE DISODIUM AREDIA Moderate or severe hypercalcemia associated with malignancy
Moderate to severe Paget’s disease of bone
Osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma
Zoledronic acid M05BA08 D01968 ZOMETA ZOMETA Hypercalcemia of malignancy
Multiple myeloma and bone metastases of solid tumors
Cytoprotector (reactive species antagonist) Dexrazoxane V03AF02 D03730 SAVENE SAVENE
V03AF02 D07807 ZINECARD Cardiomyopathy associated with metastatic breast cancer
Amifostine V03AF05 D00226 AMIFOSTINE Cumulative renal toxicity associated with advanced ovarian cancer
Somatostatin analog Octreotide H01CB02 D02250
Carcinoid tumors
Vasoactive intestinal peptide tumors
Lanreotide H01CB03 D04666 SOMATULINE Gastroenteropancreatic neuroendocrine tumors
Substituted melanine Altretamine L01XX03 D02841 HEXALEN Persistent or recurrent ovarian cancer
Substitued urea Hydroxycarbamide L01XX05 D00341 HYDREA HYDREA Melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary
Adrenocortical suppressant Mitotane L01XX23 D00420 LYSODREN OPEPRIM Inoperable adrenal cortical carcinoma of both functional and nonfunctional types
Platelet-reducing agent Anagrelide L01XX35 D02933
AGRYLIN AGRYLIN Thrombocythemia, secondary to myeloproliferative neoplasms
Histone deacetylase inhibitor Vorinostat L01XX38 D06320 ZOLINZA ZOLINZA Cutaneous T-cell lymphoma
Panobinostat L01XX42 D10019 FARYDAK FARYDAK Multiple myeloma
Belinostat L01XX49 D08870 BELEODAQ Relapsed or refractory peripheral T-cell lymphoma
Other antineoplastic agent Asparaginase L01XX02 D02997 ERWINAZE LEUNASE Acute lymphoblastic leukemia with hypersensitivity to E. coli-derived asparaginase
Pegaspargase L01XX24 D05387 ONCASPAR Acute lymphoblastic leukemia
Arsenic trioxide L01XX27 D02106 TRISENOX TRISENOX Acute promyelocytic leukemia with t(15;17) translocation or PML/RAR-alpha gene expression
Romidepsin L01XX39 D06637 ISTODAX Cutaneous T-cell lymphoma
Peripheral T-cell lymphoma
Omacetaxine L01XX40 D08956 SYNRIBO Chronic or accelerated phase chronic myeloid leukemia

Last updated: November 14, 2017